TGF-β/Smad Signaling


The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
-
B6302 SC-9Summary: protein kinase C activator -
B6343 C-1Summary: protein kinase C inhibitor -
B6803 Rottlerin4 CitationTarget: PKC|Ca2 /calmodulin-dependent protein kinases (CaMKs)|PRAK|MAPKAP-K2Summary: PKC inhibitor -
B7595 Bisindolylmaleimide IISummary: protein kinase C (PKC) inhibitor -
B1287 Ro 31-8220Target: PKCSummary: pan-PKC inhibitor -
B1693 Cetrimonium Bromide (CTAB)Summary: Component of the broad-spectrum antiseptic cetrimide -
B2191 Dequalinium ChlorideTarget: PKC|Calcium-Activated Potassium (KCa) ChannelsSummary: anti-tumor agent and PKC inhibitor -
B2287 LY3649474 CitationSummary: inhibitor of TGF-β type I receptor kinase domain -
B2114 Mitoxantrone HCl2 CitationTarget: Pim|Topoisomerases|USP|HIV IntegrasesSummary: Topoisomerase II inhibitor, anti-neoplastic drug -
B2288 PirfenidoneSummary: TGF-β production inhibitor
